Quantcast
Last updated on April 20, 2014 at 19:30 EDT

Latest Sildenafil Stories

2013-11-19 12:29:20

Largest Prospective, Multi-Year, Physician-Led Registry Advances Understanding of Real-World Satisfaction with Penile Prostheses MINNEAPOLIS, Nov. 19, 2013 /PRNewswire/ -- American Medical Systems(®) (AMS), Inc. an Endo Health Solutions Inc. (Nasdaq: ENDP) subsidiary and leading provider of devices and therapies for male and female pelvic health, today announced the enrollment of the 500th patient in the largest multi-year, prospective global registry study of penile prosthetic...

2013-11-19 08:27:51

Blockbuster drug has treated an estimated 41 million patients around the globe INDIANAPOLIS, Nov. 18, 2013 /PRNewswire/ -- Cialis is turning 10. As Cialis marks its 10(th) anniversary this week, Lilly is looking back on the last decade in men's health. Conversations that used to be taboo for men are now taking place in bedrooms and exam rooms. Men with conditions like erectile dysfunction (ED) are talking more openly with their partners and their physicians.(1) Part of this evolution was the...

2013-11-05 12:28:30

Erectile Dysfunction Treatment Platform Allows Men with ED to Connect with Local Doctors Discreetly NEW YORK, Nov. 5, 2013 /PRNewswire/ -- ErectileDoctor.com, the first website that addresses and offers resources to the over 30 million men in the United States dealing with erectile dysfunction (ED), today announced the platform has come out of beta after 12 months of testing. The company also publicized the availability of the following features including "Find a Physician," which...

2013-10-28 12:25:24

WHIPPANY, N.J., Oct. 28, 2013 /PRNewswire/ -- Bayer HealthCare today announced preliminary results from two ongoing, open-label, long-term extension studies investigating its recently approved Adempas(®) (riociguat) tablets will be presented in scientific forum at CHEST 2013, the annual meeting of the American College of Chest Physicians, October 26 - 31, in Chicago, IL. Adempas was approved by the United States Food and Drug Administration on October 8, 2013 for: (i) the treatment of...

2013-10-25 08:24:55

Study Data Shows Cialis 5 mg Initiated with Finasteride Provides Significantly Greater Improvements in Urinary Symptoms of Benign Prostatic Hyperplasia than Placebo with Finasteride INDIANAPOLIS, Oct. 25, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a product label addition for CIALIS to include data from a 26-week study that showed CIALIS 5 mg for once daily use started in combination with finasteride...

2013-10-21 08:28:11

ALBANY, New York, October 21, 2013 /PRNewswire/ -- According to a new market report published by Transparency Market Research "Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) -Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global erectile dysfunction drugs market was valued at USD 4.3 billion in 2012 and is expected to decline at a CAGR of (4.5%) from 2013 to 2019, to...

2013-10-09 08:27:05

First and only drug approved in U.S. to Treat Two Forms of Pulmonary Hypertension (WHO Group 1 and 4) WHIPPANY, N.J., Oct. 9, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the United States Food and Drug Administration (FDA) has approved Adempas(®) (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO* Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO...

2013-10-08 20:22:34

First and only drug approved in U.S. to Treat Two Forms of Pulmonary Hypertension (WHO Group 1 and 4) WHIPPANY, N.J., Oct. 8, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the United States Food and Drug Administration (FDA) has approved Adempas(®) (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO* Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO...

2013-09-30 14:13:54

New research in The FASEB Journal suggests that C6', a compound that releases nitric oxide in the body, prevented abnormalities associated with priapism in mice with and without sickle cell disease It's not the little blue pill famous for helping men get big results, but for those who need it, the outcome might be even more significant. A new research report published online in The FASEB Journal, offers hope to men who experience priapism. This condition, which is often seen in men with...

2013-07-16 08:29:40

Data published in the Journal of Sexual Medicine INDIANAPOLIS, July 16, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that study results published in the Journal of Sexual Medicine showed a greater percentage of men who had an incomplete response to as-needed PDE5 inhibitor treatment returned to normal erectile function when given Cialis once daily, compared to placebo, as measured by the erectile function domain of the International Index of Erectile...